Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of AZD4604 in Mild Asthma
NCT06732882Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of londamocitinib in asthma (5 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed drug concentration at Day 10, Time to reach maximum observed concentration at Day 10 and 5 more. Started Feb 2025; status: completed.
02
Drugs
londamocitinib
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06732882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732882.